Lineage Cell Therapeutics (LCTX) H.C. Wainwright 4th Annual Ophthalmology Virtual Conference summary

Financial and operational overview

• Reported financial position of approximately $38 million, supporting operations into Q4 next year.

• Workforce consists of about 75 employees, mainly in Southern California, with manufacturing in Israel.

Lead asset and clinical focus

• OpRegen, an RPE cell transplant for dry AMD, targets a major unmet need with few effective therapies.

• RPE cells are manufactured from pluripotent cell lines, enabling scalable, off-the-shelf therapy.

• Manufacturing process achieves high purity, reproducibility, and cost efficiency.

Strategic partnerships and clinical progress

• Secured a $670 million partnership with Roche and Genentech, including a $50 million upfront payment.

• Expanded collaboration with Genentech after initial clinical progress, despite industry-wide program reductions.